Surprising
Two specific Bacillus coagulans strains beat out common probiotics for abdominal pain in a meta-analysis of 81 IBS trials — but the dose wasn't specified.
Bacillus coagulans MTCC 5856 and Unique IS2 were ranked as top performers for reducing abdominal pain in a large meta-analysis, but because the dose was not reported and only three small studies underlie the finding, the result should be treated as promising but not definitive.
A systematic review and network meta-analysis of 81 randomized controlled trials (total 9,253 participants) found that the specific probiotic strains Bacillus coagulans MTCC 5856 and Bacillus coagulans Unique IS2 were among the most effective for improving abdominal pain in people with IBS. Both strains scored extremely high (96.9% and 92.6% on a standard ranking scale), but the dose used in the studies was not reported, and the evidence is based on only three studies total for these strains. The findings are noteworthy because they single out two relatively lesser-known strains over more commonly used probiotics for abdominal pain — a symptom that matters deeply to IBS sufferers.
Where this fits in the evidence
Pillser has synthesized 3 studies on Bacillus coagulans MTCC 5856 for Reduced Abdominal Pain — overall evidence strength: Moderate.
Across 3 studies, all reported beneficial effects on abdominal pain, with two showing large effect sizes and one moderate. The typical dose was 2 × 10^9 CFU/day (2 billion spores). Evidence primarily in adults with Irritable Bowel Syndrome (IBS) or functional gas and bloating.
The study
- Systematic Review
- n = 9,253
- 2023-09-04
- Nutrients
- PubMed: 37686889
- DOI: 10.3390/nu15173856
- Full study breakdown →
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.